$1.84Day Range$2.20
Key Statistics
Market Cap
$224.52M
Shares Outstanding
111.7M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Sep 9, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$1.86
Day High
$2.20
Day Low
$1.84
Volume
210.9K
VWAP
$2.00
Prev Close
$1.86
Transactions
--
Acc. Volume
--
About Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Identifiers
- CIK
- 0001598599
- Composite FIGI
- BBG009ZCBVG7
- Share Class FIGI
- BBG009ZCBWH4
- Ticker Root
- IPHA
About Innate Pharma S.A. ADS (IPHA) Stock
Innate Pharma S.A. ADS (IPHA) closed the 2026-09-16 session at $2.01, up 8.06% versus the previous close (+0.15). The stock opened at $1.86 and traded between $1.84 and $2.20 during that session. Session trading volume was 211K shares. The volume-weighted average price (VWAP) is $2.00.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Innate Pharma S.A. ADS has a market capitalization of $224.5 million. IPHA is listed on the XNAS exchange. The company employs approximately 163 people. The recorded listing date is 2015-09-09.
On this page you can find market IPHA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.